Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Crispr Therapeutics AG ( (CRSP) ) just unveiled an update.
On June 26, 2025, CRISPR Therapeutics AG announced updates on its in vivo cardiovascular disease programs, including new data for CTX310™, CTX320™, and CTX340™. CTX310™, targeting ANGPTL3, continues to show promising results in reducing triglycerides and low-density lipoprotein in its Phase 1 trial, with peak reductions of up to 82% and 86% respectively, without significant liver enzyme changes. CTX320™, targeting the LPA gene, is in an ongoing Phase 1 trial, with an update expected in the first half of 2026. Meanwhile, CTX340™, targeting angiotensinogen for refractory hypertension, is progressing through preclinical studies. These developments highlight CRISPR Therapeutics AG’s strategic advancements in addressing cardiovascular diseases, potentially impacting its market position and offering new treatment avenues for patients.
The most recent analyst rating on (CRSP) stock is a Hold with a $59.00 price target. To see the full list of analyst forecasts on Crispr Therapeutics AG stock, see the CRSP Stock Forecast page.
Spark’s Take on CRSP Stock
According to Spark, TipRanks’ AI Analyst, CRSP is a Neutral.
Crispr Therapeutics AG’s stock score reflects significant financial challenges and valuation concerns, offset somewhat by positive technical indicators and strategic corporate events. The company’s reliance on collaborations for revenue and external funding for liquidity are key risks. However, recent partnerships and shareholder approvals offer some optimism for strategic growth.
To see Spark’s full report on CRSP stock, click here.
More about Crispr Therapeutics AG
CRISPR Therapeutics AG operates in the biotechnology industry, focusing on developing transformative gene-based medicines. The company is primarily engaged in creating therapies for serious diseases using CRISPR/Cas9 gene-editing technology, with a significant market focus on cardiovascular diseases.
Average Trading Volume: 2,336,627
Technical Sentiment Signal: Sell
Current Market Cap: $4.12B
Find detailed analytics on CRSP stock on TipRanks’ Stock Analysis page.